文献速递关节外科创伤骨科

凝血因子XI及XIa抑制剂用于全膝关节置换术后静脉血栓栓塞预防:从机制到III期试验的综述

Factor XI and XIa Inhibitors for Venous Thromboembolism Prophylaxis After Total Knee Arthroplasty: A Review From Mechanism to Phase III Trials.
PubMed 文献 · J Arthroplasty · 2026-06-09

本文综述靶向凝血因子XI(FXI)及活化FXI(FXIa)用于全膝关节置换术(TKA)后静脉血栓栓塞(VTE)预防的生物学依据、已完成的骨科临床证据及正在进行的III期试验设计。已有II期项目显示抗FXI分子大幅降低静脉造影VTE且出血特征与依诺肝素相当,两项III期试验将评估其能否在当代关节置换实践中兼顾VTE预防与减少出血及伤口并发症。

要点

  • FXI/FXIa位于内源性通路上游,可能更多参与血栓形成而较少影响止血。
  • II期项目显示抗FXI分子大幅降低静脉造影VTE,出血特征与依诺肝素相当。
  • 两项III期试验将评估抗FXI策略能否兼顾VTE预防与减少出血及伤口并发症。

核心结论

  • 抑制FXI/FXIa可能成为下一代TKA后血栓预防策略,靶向凝血驱动的血栓形成并可能保留止血功能。
  • 正在进行的III期试验对确定抗FXI策略能否在当代关节置换实践中改善VTE预防并减少出血和伤口相关并发症至关重要。

研究设计与样本

  • 综述总结了靶向FXI/FXIa的生物学依据,汇总了已完成的各种FXI/XIa模态的骨科临床证据,并详述了正在进行的抗FXI分子TKA后预防III期试验的设计特征。

主要发现

  • FXI和FXIa位于内源性通路上游,可能相对于止血而言不成比例地促进血栓形成。
  • 在骨科手术中,多个II期项目包括反义寡核苷酸敲低FXI、单克隆抗体阻断FXI或FXIa以及小分子FXIa抑制剂,已显示大幅减少静脉造影VTE,且出血特征与依诺肝素相当。
  • 这些数据加速了后期开发,目前有两项正在进行的抗FXI分子关键III期项目,其设计旨在与当代关节置换实践模式一致并解决与外科医生最相关的证据空白。

关键数值与推荐

  • 当代实践已转向阿司匹林用于许多低风险TKA后患者的预防,直接口服抗凝药(DOAC)和低分子量肝素(LMWH)保留给较高风险患者。
  • 阿司匹林不是抗凝药,尽管广泛使用,但不直接针对凝血驱动的血栓形成,同时仍增加出血风险,尤其是胃肠道出血。
  • DOAC和LMWH仍影响共同通路的凝血酶生成,可能增加出血或损害伤口愈合。

临床怎么用

  • 临床需在减少症状性深静脉血栓和肺栓塞与最小化出血、伤口并发症及下游感染风险之间平衡。
  • 抗FXI策略可能为TKA后VTE预防提供新选择,但需等待III期试验结果确定其获益与风险。

局限性

  • 本文为综述,未报告原始研究的具体样本量、阈值、剂量或P值等数据。
  • 抗FXI分子的III期试验尚未完成,其疗效和安全性结论待定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Venous thromboembolism (VTE) prophylaxis after total knee arthroplasty (TKA) has improved substantially, yet the field continues to balance two competing priorities: reduction of symptomatic deep vein thrombosis and pulmonary embolism while minimizing bleeding, wound complications, and downstream infection risk. Contemporary practice has shifted toward aspirin as prophylaxis for many low-risk patients after TKA, with direct oral anticoagulants (DOAC) and low-molecular-weight heparin (LMWH) reserved for higher-risk patients; however, these agents still affect common-pathway thrombin generation and can increase bleeding or compromise wound healing. Aspirin is not an anticoagulant and, despite its widespread use, does not directly address coagulation-driven thrombosis while still increasing bleeding risk, particularly gastrointestinal bleeding. METHODS: This review summarizes the biologic rationale for targeting factor XI (FXI) and activated FXI (FXIa), synthesizes completed orthopaedic clinical evidence across various FXI/XIa modalities, and details the design features of ongoing Phase III trials evaluating anti-FXI molecules for post-TKA prophylaxis. RESULTS: The FXI and FXIa sit upstream in the intrinsic pathway and may contribute disproportionately to thrombosis relative to hemostasis. In orthopaedic surgery, multiple phase II programs, including antisense oligonucleotide knockdown of FXI, monoclonal antibody blockade of FXI or FXIa, and small-molecule FXIa inhibitors, have demonstrated large reductions in venographic VTE with low bleeding profiles comparable to enoxaparin. These data have accelerated late-stage development, as there are two ongoing pivotal phase III programs of anti-FXI molecules, designed to align with modern arthroplasty practice patterns and to address the evidence gaps most relevant to surgeons. CONCLUSIONS: Inhibition of FXI/FXIa may represent the next generation of post-TKA thromboprophlaxis by targeting coagulation-driven thrombosis while potentially preserving hemostasis. Ongoing Phase III trials will be critical in determining whether anti-FXI strategies can improve VTE prevention while minimizing bleeding and wound-related complications in contemporary arthroplasty practice.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Smitterberg CW, Ando W, Chen AF, et al. Factor XI and XIa Inhibitors for Venous Thromboembolism Prophylaxis After Total Knee Arthroplasty: A Review From Mechanism to Phase III Trials. J Arthroplasty. 2026. PMID: 42264107. doi:10.1016/j.arth.2026.06.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。